Literature DB >> 12559948

Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF-1alpha nuclear translocation.

Dimitrios Zgouras1, Astrid Wächtershäuser, Daniela Frings, Jürgen Stein.   

Abstract

Butyrate is known to stimulate proliferation of normal crypt cells, whereas it inhibits growth and induces apoptosis in colon cancer cells. We examined the effects of butyrate on colon cancer (Caco-2) cell-induced angiogenesis. HUVEC proliferation was significantly inhibited when incubated with medium conditioned by butyrate-treated Caco-2 cells. Simultaneously, levels of the proangiogenic vascular endothelial growth factor (VEGF) were reduced. HIF-1alpha protein, a transcription factor known to be a key regulator in hypoxia-induced angiogenesis, was upregulated by butyrate. This is in contrast to its importance as a VEGF regulating component. However Western blot of nuclear extracts revealed a downregulation of HIF-1alpha protein. HIF-1alpha DNA-binding activity was also decreased by butyrate. Our findings indicate that HIF-1alpha nuclear sequestration is repressed by butyrate, through inhibition of nuclear translocation. We postulate that diminished HIF-1alpha nuclear presence and activity in butyrate-treated Caco-2 cells could be responsible for decreased VEGF expression and antiangiogenic effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559948     DOI: 10.1016/s0006-291x(02)02916-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

Review 1.  Preoperative portal vein embolization in liver cancer: indications, techniques and outcomes.

Authors:  Romaric Loffroy; Sylvain Favelier; Olivier Chevallier; Louis Estivalet; Pierre-Yves Genson; Pierre Pottecher; Sophie Gehin; Denis Krausé; Jean-Pierre Cercueil
Journal:  Quant Imaging Med Surg       Date:  2015-10

Review 2.  Portal vein embolization before major hepatectomy.

Authors:  Hai Liu; Yong Fu
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

3.  Butyrate increases the formation of anti-angiogenic vascular endothelial growth factor variants in human lung microvascular endothelial cells.

Authors:  J Ciura; P P Jagodziński
Journal:  Mol Biol Rep       Date:  2010-03-07       Impact factor: 2.316

Review 4.  Diet, microorganisms and their metabolites, and colon cancer.

Authors:  Stephen J D O'Keefe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-16       Impact factor: 46.802

5.  The HIV protease inhibitor ritonavir synergizes with butyrate for induction of apoptotic cell death and mediates expression of heme oxygenase-1 in DLD-1 colon carcinoma cells.

Authors:  Heiko Mühl; Jens Paulukat; Sonja Höfler; Markus Hellmuth; Rochus Franzen; Josef Pfeilschifter
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

Review 6.  Effects of histone deacetylase inhibitors on HIF-1.

Authors:  Dongming Liang; Xianguo Kong; Nianli Sang
Journal:  Cell Cycle       Date:  2006-09-13       Impact factor: 4.534

Review 7.  Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.

Authors:  Shuyang Chen; Nianli Sang
Journal:  J Biomed Biotechnol       Date:  2010-12-05

8.  Diet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans.

Authors:  Junhai Ou; Franck Carbonero; Erwin G Zoetendal; James P DeLany; Mei Wang; Keith Newton; H Rex Gaskins; Stephen J D O'Keefe
Journal:  Am J Clin Nutr       Date:  2013-05-29       Impact factor: 7.045

9.  Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha.

Authors:  Donna M Fath; Xianguo Kong; Dongming Liang; Zhao Lin; Andrew Chou; Yubao Jiang; Jie Fang; Jaime Caro; Nianli Sang
Journal:  J Biol Chem       Date:  2006-03-15       Impact factor: 5.157

Review 10.  Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1).

Authors:  Dale G Nagle; Yu-Dong Zhou
Journal:  Curr Drug Targets       Date:  2006-03       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.